The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer
2007

Aromatase Inhibitors for Breast Cancer Treatment and Prevention

Sample size: 185000 publication 10 minutes Evidence: high

Author Information

Author(s): Fabian C J

Primary Institution: University of Kansas Medical Center

Hypothesis

Are aromatase inhibitors more effective than tamoxifen for treating hormone receptor-positive breast cancer?

Conclusion

Aromatase inhibitors are now preferred for treating hormone receptor-positive breast cancer in postmenopausal women and show promise in prevention.

Supporting Evidence

  • Aromatase inhibitors have largely replaced tamoxifen as the preferred treatment for hormone receptor-positive breast cancer.
  • Adverse events associated with both drug classes are manageable.
  • Current studies are testing AIs for breast cancer prevention in high-risk women.

Takeaway

Aromatase inhibitors help treat breast cancer by blocking estrogen, which can fuel cancer growth. They are often better than older treatments like tamoxifen.

Methodology

Expert opinion based on review of literature on relevant clinical trials.

Potential Biases

The author has received funding from pharmaceutical companies, which may influence the findings.

Limitations

The study primarily focuses on postmenopausal women and may not apply to premenopausal women.

Participant Demographics

Postmenopausal women with hormone receptor-positive breast cancer.

Statistical Information

P-Value

0.005

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/j.1742-1241.2007.01587.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication